Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Recently Viewed
Listening...
Show Search
Menu
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,913 Results
Date
All Dates (1913)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1913)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
1,913 results
Filters
Date
All Dates (1913)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1913)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
Sort By:
Newest
Newest
Relevance
Oldest
February 9, 2024
Johnson & Johnson highlights innovation in hemolytic disease of the fetus and newborn (HDFN) at the Society for Maternal-Fetal Medicine’s (SMFM) 2024 Pregnancy Meeting
Presentations include additional analyses of nipocalimab data from pregnancies at risk for early-onset severe HDFN; Nipocalimab is the only anti-FcRn being studied in this rare and potentially life-threatening two-person disease for which there are no approved non-surgical therapies
Read more
February 9, 2024
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development for this serious, life-threatening and rare condition
Read more
February 8, 2024
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with amivantamab plus lazertinib versus osimertinib1 Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating and resistance EGFR mutations and MET mutations and amplifications2,3,4,5
Read more
February 8, 2024
Biosense Webster Supports Collaborative Studies That Aim to Expand Knowledge in Pulsed Field Ablation
Read more
February 7, 2024
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary endpoints including PASIa 100 and IGAb 0 responses of 40.5 percent and 45.2 percent, respectively
Read more
February 7, 2024
CERENOVUS Launches Next Generation Catheter for Revascularization of Patients with Acute Ischemic Stroke
Next-generation intermediate catheter, CEREGLIDE™ 71 Intermediate Catheter with TruCourse™, now available across the U.S.
Read more
February 5, 2024
Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)
Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for efficacious, safe therapies that offer sustained disease control Nipocalimab is the first investigational anti-FcRn to show efficacy in SjD, one of the most prevalent, debilitating autoantibody diseases that has no approved advanced treatments In the past 12 months, nipocalimab has demonstrated clinical effect in four different autoantibody-driven diseases
Read more
February 2, 2024
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
Read more
February 2, 2024
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes
Read more
February 2, 2024
Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation
Retrospective Analysis of Real-World Data Presented as Late-Breaker at 29th Annual International AF Symposium
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue